BLOCK COPOLYMERS FOR STABLE MICELLES

• US 20140127271A1
• Filed: 09/16/2013
• Published: 05/08/2014
• Est. Priority Date: 04/11/2012
• Status: Abandoned Application

• Current Assignee: Intezyne Technologies
• Original Assignee: Intezyne Technologies
• Inventors: Sill, Kevin, Sheshbaradaran, Hooshmand
• Application Number:
  US14/028,485
• Publication Number:
  US 20140127271A1
• Time in Patent Office: Days
• US Class Current: 424/400
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/42 Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein oligopeptides having up to five amino acids A61K47/183; polyamino acids A61K47/34
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: C08F 283/06 on to polyethers, polyoxymethylenes or polyacetals C08F283/004 takes precedence
• CPC Class Codes: C08G 69/10 Alpha-amino-carboxylic acids polysuccinimides C08G73/1092
• CPC Class Codes: C08G 69/40 Polyamides containing oxygen in the form of ether groups C08G69/12, C08G69/32 take precedence

Abstract

The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.

Claims

1. A micelle comprising a triblock copolymer, wherein said micelle has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell, wherein the triblock copolymer is of formula VII:

2. A micelle according to claim 1, wherein the drug is a tyrosine kinase inhibitor.

3. A micelle according to claim 1, wherein the drug is LY2835219.

4. A micelle according to claim 1, wherein the drug is LCL161.

5. A micelle according to claim 1, wherein the drug is [tris(8-quinolinolato)gallium(III)].